AOTI's 65-Fold Promise, Told Against a Year That Didn't Move
A $138M wound-care micro-cap stakes its future on a Medicare coverage determination that won't pay out until 2027 — and quietly retreats from Arizona in the meantime.
AOTI.L · Earnings Call · 2026-09-30
The whole thesis in a single capital-markets document
Most small-cap results calls are a shuffle of small numbers. AOTI's half-year update is different because it is built around one discrete, datable event: in July 2026, CMS published a proposed Local Coverage Determination deeming topical oxygen "reasonable and necessary" for treating Medicare patients — the over-65 population where chronic wounds concentrate. The company frames this as the hinge of its entire existence. Management is blunt that the topical oxygen platform is "already the leader in the topical oxygen space," differentiated not just by clinical utility but by delivering "longer, more durable healing of chronic wounds."
The scale of the multiplier is the headline: serviceable market today, anchored on the Department of Veterans Affairs nationwide and New York State Medicaid, is roughly 28,000 difficult-to-heal wounds — a ~$400M opportunity the company believes it has penetrated less than 20%. With Medicare coverage flushing through, management puts the addressable market at 1.8 million wounds. “this will open up access to not just the Medicare, the over 65... but will also is used as a bellwether for all other payer groups” — Mike Griffiths, Chief Executive Officer · 2026-09-30 — the 65-fold framing comes straight from the CEO.
That is a genuinely company-unique catalyst. You will not find it anywhere in the global tape for the quarter, whose editor-curated themes are a wall of tariff refunds and IEEPA minutiae. AOTI is an idiosyncratic island in a macro-noise quarter.
The tension: a transformational story bolted to static numbers
Here is where the dossier gets interesting. The words are expansive; the guidance is not. Underlying revenue grew ~18.8% excluding Arizona, but reported growth was only 10.8%. EBITDA rose 16.6% to $3.6M, a 10.1% margin — up just 50 basis points. Operating cash flow swung positive to $0.9M from a $4.7M outflow, and net debt improved a sliver to $6.3M. Full-year 2026 EBITDA is expected "in line with current consensus" of $6.8M.
So the CMS decision — the thing described as "transformational" — does not touch the current-year P&L at all. It is a 2027 event, and management is honest about that: the final determination is statutory within 365 days, plus a further mandatory waiting period before codes become billable, plus the un-decided question of what Medicare will pay. On price, Mike Griffiths gave the rare specifics: VA pays roughly $3,000–$3,100 per month under a Federal Supply Schedule contract, which acts as a "most favored nation" backstop, while other payers reimburse "nearly always around double or more than that." The expectation is a clearing price somewhere between. That is an unmade decision sitting underneath 65x of modeled market.
The offsetting signal is margin quality. The 10.1% grew despite deliberate spending: “if you weren't making those investments in growth, you could see that our profitability could be up to 20% rather than 10%” — Jayesh Pankhania, Chief Financial Officer · 2026-09-30. In other words, the CFO is implicitly asking investors to underwrite a scalable operating-leverage story whose payoff is deferred until the coverage becomes billable.
The piece management stopped emphasizing: Arizona
The most telling move this half is a subtraction, not an addition. On April 1, 2026, AOTI ceased treating new Arizona Medicaid patients — a state where it had been billing without collecting, caught in cyber-breaches, insurer turbulence, CTP fraud, and repeated Medicaid director changes. “We took the difficult decision on the 1st of April to cease the treatment of new patients from Arizona Medicaid” — Jayesh Pankhania, Chief Financial Officer · 2026-09-30. The company is confident it recovers the historical debt but conceded timing is "really difficult to say." It also renegotiated revenue and EBITDA covenants on its Rodeo loan in September to prudently lower them.
Read against the expansion narrative, this is the tension the call dances around: management is simultaneously arguing the market is about to 65x and walking away from a state Medicaid book it cannot collect. The culprit is partly macro. Pressed on why new-state Medicaid coverage is stalling, management points to U.S. healthcare headwinds and the "One Big Beautiful Bill Act" ratcheting down Medicaid support — a live, market-wide theme. The global keyword feed flagged the Big Beautiful legislation as a broad theme two quarters ago; AOTI is now one of its concrete casualties, and it is the reason Medicaid expansion — the growth engine before Medicare — is being "hampered."
The moat, the productivity lever, and the KCI ghost
The bull case rests on durability being real, not marketing. Management cites a real-world study of 3,000-plus patients showing not just healing but large reductions in reoccurrence and hospitalizations, and “we heal 6 times more effectively than standard of care... we have as much as a sixfold reduction in reoccurrence over 12 months or longer” — Mike Griffiths, Chief Executive Officer · 2026-09-30. The clinical-rigor thread extends to a pending venous-leg-ulcer trial — Venous leg ulcers already represent roughly 15% of treated patients — which, if it lands, widens the CMS indications further.
The nearer-term earnings lever is rep productivity. Average is about 20 patients per rep, but “our highest performing reps, they are producing as much as five times as many as that” — Mike Griffiths, Chief Executive Officer · 2026-09-30. Closing the median toward the top, ideally doubling the average, is the operating story that funds the wait for Medicare. The restructuring — making once sector-specific sales teams geographic, and reworking commission so underperformers earn less — is the mechanism.
And the framing device management chose is revealing: the KCI analogy. Negative-pressure wound therapy received Medicare coverage in late 2000 and, per management's telling, compounded to roughly a $1.5B product line that still dominates 25 years later. It is an explicit invitation to compare AOTI to a category creator at the moment of coverage. That is a confident pitch — arguably promotional — for a company with a $138M market cap and no price tape supplied in the context to corroborate that the market is buying any of it.
What actually changed
The honest read: almost nothing changed in the financials, and everything changed in the story. A micro-cap that spent years begging for a CMS decision got one — a proposed, universally-supported, statutorily-timed path to national coverage. Against that, it lost Arizona, watched Medicaid expansion stall under federal budget pressure, guided to unchanged full-year numbers, and pushed the entire payoff into 2027 and beyond, at a reimbursement price not yet set. The stock does not appear in any advancer/decliner cluster, so there is no tape to tell us whether the market has begun to price the 65x — or the Arizona hole. For now, this is a story about a company that has finally seen the door crack open, standing at the threshold, waiting for the system to say it can walk through.